|
1
|
Kilcline C and Frieden IJ: Infantile
hemangiomas: How common are they? A systematic review of the
medical literature. Pediatr Dermatol. 25:168–173. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chang LC, Haggstrom AN, Drolet BA, Baselga
E, Chamlin SL, Garzon MC, Horii KA, Lucky AW, Mancini AJ, Metry DW,
et al: Growth characteristics of infantile hemangiomas:
Implications for management. Pediatrics. 122:360–367. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chen TS, Eichenfield LF and Friedlander
SF: Infantile hemangiomas: An update on pathogenesis and therapy.
Pediatrics. 131:99–108. 2013. View Article : Google Scholar
|
|
4
|
Sethuraman G, Yenamandra VK and Gupta V:
Management of infantile hemangiomas: Current trends. J Cutan
Aesthet Surg. 7:75–85. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Léaute-Labrèze C, Boccara O,
Degrugillier-Chopinet C, Mazereeuw-Hautier J, Prey S, Lebbé G,
Gautier S, Ortis V, Lafon M, Montagne A, et al: Safety of oral
rapamycin for the treatment of infantile hemangioma: A Systematic
Review. Pediatrics. 138:pii: e20160353. 2016. View Article : Google Scholar
|
|
6
|
Kaur A and Sharma S: Mammalian target of
rapamycin (mTOR) as a potential therapeutic target in various
diseases. Inflammopharmacology. 25:293–312. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Del Bufalo D, Ciuffreda L, Trisciuoglio D,
Desideri M, Cognetti F, Zupi G and Milella M: Antiangiogenic
potential of the Mammalian target of rapamycin inhibitor
temsirolimus. Cancer Res. 66:5549–5554. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Medici D and Olsen BR: Rapamycin inhibits
proliferation of hemangioma endothelial cells by reducing
HIF-1-dependent expression of VEGF. PLoS One. 7:e429132012.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zheng N, Ding X and Jahan R: Low
concentration of rapamycin inhibits hemangioma endothelial cell
proliferation, migration, and vascular tumor formation in mice.
Curr Ther Res Clin Exp. 76:99–103. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Johnson RW: Sirolimus (Rapamune) in renal
transplantation. Curr Opin Nephrol Hypertens. 11:603–607. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Stallone G, Infante B, Grandaliano G and
Gesualdo L: Management of side effects of sirolimus therapy.
Transplantation. 87(8 Suppl): S23–S26. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Almeida H, Amaral MH, Lobao P, Frigerio C
and Sousa Lobo JM: Nanoparticles in ocular drug delivery systems
for topical administration: Promises and challenges. Curr Pharm
Des. 21:5212–5224. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li H, Teng Y, Sun J and Liu J: Inhibition
of hemangioma growth using lipid polymer nanoparticles for delivery
of rapamycin. Biomed Pharmacother. 95:875–884. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gao J, Chen H, Song H, Su X, Niu F, Li W,
Li B, Dai J, Wang H and Guo Y: Antibody-targeted immunoliposomes
for cancer treatment. Mini Rev Med Chem. 13:2026–2035. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gao J, Feng SS and Guo Y: Antibody
engineering promotes nanomedicine for cancer treatment.
Nanomedicine (Lond). 5:1141–1145. 2010. View Article : Google Scholar
|
|
16
|
Li W, Li J, Gao J, Li B, Xia Y, Meng Y, Yu
Y, Chen H, Dai J, Wang H and Guo Y: The fine-tuning of
thermosensitive and degradable polymer micelles for enhancing
intracellular uptake and drug release in tumors. Biomaterials.
32:3832–3844. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Eskens FA and Verweij J: The clinical
toxicity profile of vascular endothelial growth factor (VEGF) and
vascular endothelial growth factor receptor (VEGFR) targeting
angiogenesis inhibitors; a review. Eur J Cancer. 42:3127–3139.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tugues S, Koch S, Gualandi L, Li X and
Claesson-Welsh L: Vascular endothelial growth factors and
receptors: Antiangiogenic therapy in the treatment of cancer. Mol
Aspects Med. 32:88–111. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang Z, Li J, Xu X, Duan X and Cao G: Urea
immunoliposome inhibits human vascular endothelial cell
proliferation for hemangioma treatment. World J Surg Oncol.
11:3002013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Humar R, Kiefer FN, Berns H, Resink TJ and
Battegay EJ: Hypoxia enhances vascular cell proliferation and
angiogenesis in vitro via rapamycin (mTOR)-dependent signaling.
FASEB J. 16:771–780. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Nyström AM and Fadeel B: Safety assessment
of nanomaterials: Implications for nanomedicine. J Control Release.
161:403–408. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Nelson AL, Dhimolea E and Reichert JM:
Development trends for human monoclonal antibody therapeutics. Nat
Rev Drug Discov. 9:767–774. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Park JW, Hong K, Kirpotin DB, Colbern G,
Shalaby R, Baselga J, Shao Y, Nielsen UB, Marks JD, Moore D, et al:
Anti-HER2 immunoliposomes: Enhanced efficacy attributable to
targeted delivery. Clin Cancer Res. 8:1172–1181. 2002.PubMed/NCBI
|
